Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1980 Apr;99(1):13–42.

Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants.

J F Van Vleet, V J Ferrans, W E Weirich
PMCID: PMC1903483  PMID: 7361854

Abstract

Chronic adriamycin (ADR) intoxication was produced in three groups of beagle dogs by weekly intravenous injections (1 mg/kg body weight) for 20 weeks (cumulative dose 400 mg/sq m). Group A (6 dogs) received ADR only; Group B (6 dogs) were given ADR and weekly doses of vitamin E (17 mg/kg body weight) as alpha-tocopherol acetate; and Group C (6 dogs) received ADR and weekly doses of vitamin E as did Group B and selenium (0.06 mg/kg body weight as selenite). Each of the 18 dogs developed ADR-induced cardiomyopathy (CMY), and death occurred in 11 dogs during Weeks 17-20. Mortality was lowest in Group B (2 of 6), but no differences between groups were seen either in survival time of the dogs that died or in severity of CMY. Cardiomyopathy was more severe in dogs that died than in survivors. Congestive heart failure with transudation was present in 4 of 11 dogs that died. Cardiac histopathology was characterized by vacuolar degeneration of myocytes. Myocardial damage was most severe in the left ventricle and the ventricular septum, intermediate in the right ventricle and the left atrium, and least in the right atrium. Ultrastructural study showed that an early alteration in damaged myocytes was distention of sarcoplasmic reticulum to form sarcoplasmic vacuoles. Occasional damaged fibers had myofibrillar lysis and focal proliferation of sarcoplasmic reticulum. This study demonstrates that the dog offers a suitable model for studies of chronic ADR cardiotoxicity in man. The lack of cardioprotection from vitamin E and selenium supplementation fails to support the proposed role of lipoperoxidative damage in the development of chronic ADR-induced CMY.

Full text

PDF
13

Images in this article

33Figure 9
on p.33
33Figure 10
on p.33
25Figure 1
on p.25
25Figure 2
on p.25
35Figure 11
on p.35
35Figure 12
on p.35
35Figure 13
on p.35
27Figure 3
on p.27
27Figure 4
on p.27
27Figure 5
on p.27
37Figure 14
on p.37
37Figure 15
on p.37
29Figure 6
on p.29
29Figure 7
on p.29
31Figure 8
on p.31
39Figure 16
on p.39
39Figure 17
on p.39
41Figure 18
on p.41
41Figure 19
on p.41

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertazzoli C., Chieli T., Ferni G., Ricevuti G., Solcia E. Chronic toxicity of adriamycin: a new antineoplastic antibiotic. Toxicol Appl Pharmacol. 1972 Mar;21(3):287–301. doi: 10.1016/0041-008x(72)90149-4. [DOI] [PubMed] [Google Scholar]
  2. Billingham M. E., Mason J. W., Bristow M. R., Daniels J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978 Jun;62(6):865–872. [PubMed] [Google Scholar]
  3. Bristow M. R., Billingham M. E., Mason J. W., Daniels J. R. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978 Jun;62(6):873–879. [PubMed] [Google Scholar]
  4. Buja L. M., Ferrans V. J., Mayer R. J., Roberts W. C., Henderson E. S. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 1973 Oct;32(4):771–788. doi: 10.1002/1097-0142(197310)32:4<771::aid-cncr2820320407>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  5. Choe J. Y., Combs A. B., Folkers K. Prevention by coenzyme Q10 of the electrocardiographic changes induced by adriamycin in rats. Res Commun Chem Pathol Pharmacol. 1979 Jan;23(1):199–202. [PubMed] [Google Scholar]
  6. Cortes E. P., Gupta M., Chou C., Amin V. C., Folkers K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep. 1978 Jun;62(6):887–891. [PubMed] [Google Scholar]
  7. Fajardo L. F., Eltringham J. R., Steward J. R. Combined cardiotoxicity of adriamycin and x-radiation. Lab Invest. 1976 Jan;34(1):86–96. [PubMed] [Google Scholar]
  8. Ferrans V. J., Buja L. M., Maron B. J. Myofibrillar abnormalities following cardiac muscle cell injury. Recent Adv Stud Cardiac Struct Metab. 1975;6:367–382. [PubMed] [Google Scholar]
  9. Ferrans V. J. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep. 1978 Jun;62(6):955–961. [PubMed] [Google Scholar]
  10. Folkers K., Choe J. Y., Combs A. B. Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat. Proc Natl Acad Sci U S A. 1978 Oct;75(10):5178–5180. doi: 10.1073/pnas.75.10.5178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Formelli F., Zedeck M. S., Sternberg S. S., Philips F. S. Effects of adriamycin on DNA synthesis in mouse and rat heart. Cancer Res. 1978 Oct;38(10):3286–3292. [PubMed] [Google Scholar]
  12. Goodman J., Hochstein P. Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Commun. 1977 Jul 25;77(2):797–803. doi: 10.1016/s0006-291x(77)80048-x. [DOI] [PubMed] [Google Scholar]
  13. Henderson I. C., Frei T. E., 3rd Adriamycin and the heart. N Engl J Med. 1979 Feb 8;300(6):310–312. doi: 10.1056/NEJM197902083000610. [DOI] [PubMed] [Google Scholar]
  14. Hoekstra W. G. Biochemical function of selenium and its relation to vitamin E. Fed Proc. 1975 Oct;34(11):2083–2089. [PubMed] [Google Scholar]
  15. Jaenke R. S. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest. 1974 Mar;30(3):292–304. [PubMed] [Google Scholar]
  16. Jaenke R. S. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res. 1976 Aug;36(8):2958–2966. [PubMed] [Google Scholar]
  17. Jones M., Ferrans V. J. Myocardial degeneration in congenital heart disease. Comparison of morphologic findings in young and old patients with congenital heart disease associated with muscular obstruction to right ventricular outflow. Am J Cardiol. 1977 Jun;39(7):1051–1063. doi: 10.1016/s0002-9149(77)80221-x. [DOI] [PubMed] [Google Scholar]
  18. Kehoe R., Singer D. H., Trapani A., Billingham M., Levandowski R., Elson J. Adriamycin-induced cardiac dysrhythmias in an experimental dog model. Cancer Treat Rep. 1978 Jun;62(6):963–978. [PubMed] [Google Scholar]
  19. Kishi T., Folkers K. Letter: Prevention by coenzyme Q10 (NSC-140865) of the inhibition by adriamycin (NSC-123127) of coenzyme Q10 enzymes. Cancer Treat Rep. 1976 Mar;60(3):223–4?U9ENG. [PubMed] [Google Scholar]
  20. Lambertenghi-Deliliers G., Zanon P. L., Pozzoli E. F., Bellini O., Praga C. Ultrastructural alterations of atrial myocardium induced by adriamycin in chronically treated animals. Tumori. 1978 Feb 28;64(1):15–24. doi: 10.1177/030089167806400102. [DOI] [PubMed] [Google Scholar]
  21. Lefrak E. A., Pitha J., Rosenheim S., Gottlieb J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302–314. doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  22. Lenaz L., Page J. A. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev. 1976 Sep;3(3):111–120. doi: 10.1016/s0305-7372(76)80018-7. [DOI] [PubMed] [Google Scholar]
  23. Maron B. J., Ferrans V. J., Jones M. The spectrum of degenerative changes in hypertrophied human cardiac muscle cells: an ultrastructural study. Recent Adv Stud Cardiac Struct Metab. 1975;8:447–466. [PubMed] [Google Scholar]
  24. Maron B. J., Ferrans V. J., Roberts W. C. Myocardial ultrastructure in patients with chronic aortic valve disease. Am J Cardiol. 1975 May;35(5):725–739. doi: 10.1016/0002-9149(75)90065-x. [DOI] [PubMed] [Google Scholar]
  25. Maron B. J., Ferrans V. J. Ultrastructural features of hypertrophied human ventricular myocardium. Prog Cardiovasc Dis. 1978 Nov-Dec;21(3):207–238. doi: 10.1016/0033-0620(78)90026-9. [DOI] [PubMed] [Google Scholar]
  26. Mason J. W., Bristow M. R., Billingham M. E., Daniels J. R. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978 Jun;62(6):857–864. [PubMed] [Google Scholar]
  27. Mettler F. P., Young D. M., Ward J. M. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 1977 Aug;37(8 Pt 1):2705–2713. [PubMed] [Google Scholar]
  28. Myers C. E., McGuire W. P., Liss R. H., Ifrim I., Grotzinger K., Young R. C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977 Jul 8;197(4299):165–167. doi: 10.1126/science.877547. [DOI] [PubMed] [Google Scholar]
  29. Myers C. E., McGuire W., Young R. Adriamycin: amelioration of toxicity by alpha-tocopherol. Cancer Treat Rep. 1976 Jul;60(7):961–962. [PubMed] [Google Scholar]
  30. Olson H. M., Capen C. C. Chronic cardiotoxicity of doxorubicin (adriamycin) in the rat: morphologic and biochemical investigations. Toxicol Appl Pharmacol. 1978 Jun;44(3):605–616. doi: 10.1016/0041-008x(78)90268-5. [DOI] [PubMed] [Google Scholar]
  31. Olson H. M., Young D. M., Prieur D. J., LeRoy A. F., Reagan R. L. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 1974 Dec;77(3):439–454. [PMC free article] [PubMed] [Google Scholar]
  32. Revis N. W., Marusic N. Glutathione peroxidase activity and selenium concentration in the hearts of doxorubicin-treated rabbits. J Mol Cell Cardiol. 1978 Oct;10(10):945–951. doi: 10.1016/0022-2828(78)90340-1. [DOI] [PubMed] [Google Scholar]
  33. Sonneveld P. Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat. Cancer Treat Rep. 1978 Jul;62(7):1033–1036. [PubMed] [Google Scholar]
  34. Thiedermann K. U., Ferrans V. J. Ultrastructure of sarcoplasmic reticulum in atrial myocardium of patients with mitral valvular disease. Am J Pathol. 1976 Apr;83(1):1–38. [PMC free article] [PubMed] [Google Scholar]
  35. Van Vleet J. F., Greenwood L. A., Ferrans V. J. Pathologic features of adriamycin toxicosis in young pigs: nonskeletal lesions. Am J Vet Res. 1979 Nov;40(11):1537–1552. [PubMed] [Google Scholar]
  36. Van Vleet J. F., Greenwood L., Ferrans V. J., Rebar A. H. Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. Am J Vet Res. 1978 Jun;39(6):997–1010. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES